Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Does bacterial vaginosis modify the effect of hormonal contraception on HIV seroconversion.

Sabo MC, Richardson BA, Lavreys L, Martin HL Jr, Jaoko W, Mandaliya K, Baeten JM, Overbaugh J, McClelland RS.

AIDS. 2019 Jun 1;33(7):1225-1230. doi: 10.1097/QAD.0000000000002167.

PMID:
31048629
2.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

3.

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M.

SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017.

4.

Targeted screening of at-risk adults for acute HIV-1 infection in sub-Saharan Africa.

Sanders EJ, Wahome E, Powers KA, Werner L, Fegan G, Lavreys L, Mapanje C, McClelland RS, Garrett N, Miller WC, Graham SM.

AIDS. 2015 Dec;29 Suppl 3:S221-30. doi: 10.1097/QAD.0000000000000924.

5.

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.

Orrell C, Felizarta F, Nell A, Kakuda TN, Lavreys L, Nijs S, Tambuyzer L, Van Solingen-Ristea R, Tomaka FL.

AIDS Res Treat. 2015;2015:938628. doi: 10.1155/2015/938628. Epub 2015 Jan 15.

6.

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.

Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M; Etravirine Cohort Study Group.

HIV Med. 2015 May;16(5):297-306. doi: 10.1111/hiv.12218. Epub 2015 Jan 14.

7.

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults.

Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Vanveggel S, Opsomer M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19783. doi: 10.7448/IAS.17.4.19783. eCollection 2014.

8.

Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.

Kakuda TN, Sekar V, Lavreys L, De Paepe E, Stevens T, Vanstockem M, Vangeneugden T, Hoetelmans RM.

Clin Pharmacol Drug Dev. 2014 Sep;3(5):346-52. doi: 10.1002/cpdd.88. Epub 2014 Feb 10.

PMID:
27129006
9.

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.

Harrer T, Plettenberg A, Arastéh K, Van Lunzen J, Fätkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G.

Vaccine. 2014 May 7;32(22):2657-65. doi: 10.1016/j.vaccine.2013.10.030. Epub 2013 Oct 19.

10.

Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.

Arathoon E, Schneider S, Baraldi E, Lim PL, Opravil M, Van De Casteele T, Lavreys L.

Int J STD AIDS. 2013 Jan;24(1):12-7. doi: 10.1258/ijsa.2012.012120. Epub 2013 May 6.

PMID:
23440570
11.

Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.

Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A, Ballesteros J, Sosa N, Van De Casteele T, DeMasi R, Spinosa-Guzman S, Lavreys L.

HIV Clin Trials. 2011 Nov-Dec;12(6):313-22. doi: 10.1310/hct1206-313.

PMID:
22189150
12.

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.

Antivir Ther. 2011;16(1):99-108. doi: 10.3851/IMP1719.

PMID:
21311113
13.

Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.

Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, De Pauw M, Hoetelmans R.

Antimicrob Agents Chemother. 2010 Oct;54(10):4440-5. doi: 10.1128/AAC.01749-09. Epub 2010 Jul 26.

14.

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.

Nelson M, Girard PM, Demasi R, Chen L, Smets E, Sekar V, Lavreys L.

J Antimicrob Chemother. 2010 Jul;65(7):1505-9. doi: 10.1093/jac/dkq150. Epub 2010 May 24.

PMID:
20498120
15.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.

AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.

PMID:
19487905
16.

A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya.

Chohan V, Baeten JM, Benki S, Graham SM, Lavreys L, Mandaliya K, Ndinya-Achola JO, Jaoko W, Overbaugh J, McClelland RS.

Sex Transm Infect. 2009 Dec;85(7):489-92. doi: 10.1136/sti.2009.036103. Epub 2009 May 19.

17.

Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.

McClelland RS, Richardson BA, Hassan WM, Chohan V, Lavreys L, Mandaliya K, Kiarie J, Jaoko W, Ndinya-Achola JO, Baeten JM, Kurth AE, Holmes KK.

J Infect Dis. 2008 May 15;197(10):1361-8. doi: 10.1086/587490.

18.

A prospective study of risk factors for bacterial vaginosis in HIV-1-seronegative African women.

McClelland RS, Richardson BA, Graham SM, Masese LN, Gitau R, Lavreys L, Mandaliya K, Jaoko W, Baeten JM, Ndinya-Achola JO.

Sex Transm Dis. 2008 Jun;35(6):617-23. doi: 10.1097/OLQ.0b013e31816907fa.

19.

A decrease in albumin in early HIV type 1 infection predicts subsequent disease progression.

Graham SM, Baeten JM, Richardson BA, Wener MH, Lavreys L, Mandaliya K, Ndinya-Achola JO, Overbaugh J, McClelland RS.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1197-200.

PMID:
17961104
20.

Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women.

Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, Ndinya-Achola JO, Jaoko W, Overbaugh J.

AIDS. 2007 Aug 20;21(13):1771-7.

PMID:
17690576
21.

The influence of hormonal contraceptive use on HIV-1 transmission and disease progression.

Baeten JM, Lavreys L, Overbaugh J.

Clin Infect Dis. 2007 Aug 1;45(3):360-9. Epub 2007 Jun 18. Review.

PMID:
17599316
22.

Higher pre-infection vitamin E levels are associated with higher mortality in HIV-1-infected Kenyan women: a prospective study.

Graham SM, Baeten JM, Richardson BA, Bankson DD, Lavreys L, Ndinya-Achola JO, Mandaliya K, Overbaugh J, McClelland RS.

BMC Infect Dis. 2007 Jun 26;7:63.

23.

Relationship between markers of HIV-1 disease progression and serum beta-carotene concentrations in Kenyan women.

Baeten JM, McClelland RS, Wener MH, Bankson DD, Lavreys L, Mandaliya K, Bwayo JJ, Kreiss JK.

Int J STD AIDS. 2007 Mar;18(3):202-6.

PMID:
17362556
24.

HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.

Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, Jaoko W, Overbaugh J.

J Infect Dis. 2007 Apr 15;195(8):1177-80. Epub 2007 Mar 2.

PMID:
17357054
25.

Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition.

McClelland RS, Sangare L, Hassan WM, Lavreys L, Mandaliya K, Kiarie J, Ndinya-Achola J, Jaoko W, Baeten JM.

J Infect Dis. 2007 Mar 1;195(5):698-702. Epub 2007 Jan 22.

PMID:
17262712
26.

High levels of cervical HIV-1 RNA during early HIV-1 infection.

Lavreys L, Baeten JM, Panteleeff DD, Richardson BA, McClelland RS, Chohan V, Mandaliya K, Ndinya-Achola JO, Overbaugh J.

AIDS. 2006 Nov 28;20(18):2389-90.

PMID:
17117027
27.

Associations between intravaginal practices and bacterial vaginosis in Kenyan female sex workers without symptoms of vaginal infections.

Hassan WM, Lavreys L, Chohan V, Richardson BA, Mandaliya K, Ndinya-Achola JO, Kiarie J, Jaoko W, Holmes KK, McClelland RS.

Sex Transm Dis. 2007 Jun;34(6):384-8.

PMID:
17065846
28.

Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters.

Benki S, McClelland RS, Emery S, Baeten JM, Richardson BA, Lavreys L, Mandaliya K, Overbaugh J.

J Clin Microbiol. 2006 Dec;44(12):4357-62. Epub 2006 Oct 18.

29.

HIV-1 acquisition and disease progression are associated with decreased high-risk sexual behaviour among Kenyan female sex workers.

McClelland RS, Hassan WM, Lavreys L, Richardson BA, Mandaliya K, Ndinya-Achola J, Jaoko W, Kurth AE, Baeten JM.

AIDS. 2006 Oct 3;20(15):1969-73.

PMID:
16988519
30.

Low serum albumin and the acute phase response predict low serum selenium in HIV-1 infected women.

Drain PK, Baeten JM, Overbaugh J, Wener MH, Bankson DD, Lavreys L, Mandaliya K, Ndinya-Achola JO, McClelland RS.

BMC Infect Dis. 2006 May 19;6:85.

32.

HIV-1 infection alters the retinol-binding protein:transthyretin ratio even in the absence of the acute phase response.

Baeten JM, Wener MH, Bankson DD, Lavreys L, Richardson BA, Mandaliya K, Bwayo JJ, McClelland RS.

J Nutr. 2006 Jun;136(6):1624-9.

PMID:
16702331
33.

A comparison of genital HIV-1 shedding and sexual risk behavior among Kenyan women based on eligibility for initiation of HAART according to WHO guidelines.

McClelland RS, Baeten JM, Richardson BA, Lavreys L, Emery S, Mandaliya K, Ndinya-Achola JO, Overbaugh J.

J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):611-5.

PMID:
16652035
34.

Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.

Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, Richardson BA, Mandaliya K, Ndinya-Achola JO, Overbaugh J.

Clin Infect Dis. 2006 May 1;42(9):1333-9. Epub 2006 Mar 27.

PMID:
16586394
35.

Vaginal washing and increased risk of HIV-1 acquisition among African women: a 10-year prospective study.

McClelland RS, Lavreys L, Hassan WM, Mandaliya K, Ndinya-Achola JO, Baeten JM.

AIDS. 2006 Jan 9;20(2):269-73.

PMID:
16511421
36.

Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype.

Chohan B, Lavreys L, Rainwater SM, Overbaugh J.

J Virol. 2005 Aug;79(16):10701-8.

37.

Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort.

Baeten JM, Lavreys L, Sagar M, Kreiss JK, Richardson BA, Chohan B, Panteleeff D, Mandaliya K, Ndinya-Achola JO, Overbaugh J, Farley T, Mwachari C, Cohen C, Chipato T, Jaisamrarn U, Kiriwat O, Duerr A.

J Acquir Immune Defic Syndr. 2005 Mar;38 Suppl 1:S18-21. No abstract available.

PMID:
15867603
39.

Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men.

Baeten JM, Richardson BA, Lavreys L, Rakwar JP, Mandaliya K, Bwayo JJ, Kreiss JK.

J Infect Dis. 2005 Feb 15;191(4):546-53. Epub 2005 Jan 18.

PMID:
15655778
40.

Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study.

McClelland RS, Lavreys L, Katingima C, Overbaugh J, Chohan V, Mandaliya K, Ndinya-Achola J, Baeten JM.

J Infect Dis. 2005 Feb 1;191(3):333-8. Epub 2004 Dec 22.

PMID:
15633091
41.

Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women.

Lavreys L, Chohan V, Overbaugh J, Hassan W, McClelland RS, Kreiss J, Mandaliya K, Ndinya-Achola J, Baeten JM.

AIDS. 2004 Nov 5;18(16):2179-84.

PMID:
15577651
42.

Micronutrient supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial.

McClelland RS, Baeten JM, Overbaugh J, Richardson BA, Mandaliya K, Emery S, Lavreys L, Ndinya-Achola JO, Bankson DD, Bwayo JJ, Kreiss JK.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1657-63.

PMID:
15577425
43.

Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women.

Taylor MM, Chohan B, Lavreys L, Hassan W, Huang ML, Corey L, Ashley Morrow R, Richardson BA, Mandaliya K, Ndinya-Achola J, Bwayo J, Kreiss J.

J Infect Dis. 2004 Aug 1;190(3):484-8. Epub 2004 Jul 7.

PMID:
15243920
44.

Human herpesvirus 8 seroconversion in Kenyan women by enzyme-linked immunosorbent assay and immunofluorescence assay.

Chohan BH, Taylor H, Obrigewitch R, Lavreys L, Richardson BA, Mandaliya KN, Bwayo JJ, Kreiss JK, Morrow RA.

J Clin Virol. 2004 Jun;30(2):137-44.

PMID:
15125869
45.

Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study.

Lavreys L, Baeten JM, Martin HL Jr, Overbaugh J, Mandaliya K, Ndinya-Achola J, Kreiss JK.

AIDS. 2004 Mar 5;18(4):695-7. No abstract available.

PMID:
15090778
46.

Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population.

Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Ndinya-Achola JO, Kreiss JK, Overbaugh J.

AIDS. 2004 Mar 5;18(4):615-9.

PMID:
15090766
47.

The effect of hormonal contraception on genital tract shedding of HIV-1.

Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, Chohan B, Lavreys L, Ndinya-Achola J, Kreiss JK.

AIDS. 2004 Jan 23;18(2):205-9.

PMID:
15075537
48.

Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial.

Baeten JM, McClelland RS, Corey L, Overbaugh J, Lavreys L, Richardson BA, Wald A, Mandaliya K, Bwayo JJ, Kreiss JK.

J Infect Dis. 2004 Apr 15;189(8):1466-71. Epub 2004 Apr 2.

PMID:
15073684
49.

Use of serum retinol-binding protein for prediction of vitamin A deficiency: effects of HIV-1 infection, protein malnutrition, and the acute phase response.

Baeten JM, Richardson BA, Bankson DD, Wener MH, Kreiss JK, Lavreys L, Mandaliya K, Bwayo JJ, McClelland RS.

Am J Clin Nutr. 2004 Feb;79(2):218-25.

PMID:
14749226
50.

Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Lavreys L, Baeten JM, Kreiss JK, Richardson BA, Chohan BH, Hassan W, Panteleeff DD, Mandaliya K, Ndinya-Achola JO, Overbaugh J.

J Infect Dis. 2004 Jan 15;189(2):303-11. Epub 2004 Jan 9.

PMID:
14722896

Supplemental Content

Loading ...
Support Center